Top 10 reads of 2022
The News and Insight section of Cambridge Judge Business School’s website seeks a broad range of topics of interest to diverse audiences. In 2022, attention was focused on articles ranging from paedophile stings to Bitcoin, and from how edible insects…
How fellows enrich Cambridge Judge Business School
The fellows at Cambridge Judge Business School are a terrific resource that benefit the Business School and its students, says Dean Mauro Guillén in this blog post. by Professor Mauro F Guillén, Dean of Cambridge Judge Business School At Cambridge Judge…
Financial Times: FT business books – March edition
“From Breakthrough to Blockbuster”, a book co-authored by Nektarios Oraiopoulos, Associate Professor at Cambridge Judge Business School, was included in the March list of top business books of the month by the Financial Times, which says the book “tells the…
India Education Diary: New book highlights how small biotech companies are outperforming big pharma
From Breakthrough to Blockbuster: The Business of Biotechnology, a new book co-authored by Nektarios Oraiopoulos, Associate Professor at Cambridge Judge Business School, shows how small, inexperienced entrepreneurial companies making up the biotech industry have created more life-changing medicines than all…
From Breakthrough to Blockbuster
New book co-authored by Nektarios Oraiopoulos of Cambridge Judge Business School charts the rise of entrepreneurial biotech firms. Dr Nektarios Oraiopoulos From Breakthrough to Blockbuster: The Business of Biotechnology, published today, shows how the small, inexperienced entrepreneurial companies making up…
Executive Courses: Executive education courses in data analytics
Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge Business School, is quoted in the article. “Businesses and their leaders can use data to understand better, in an un-biased way, how they can create value for their customers,”…
Forbes India: How drug companies can increase their R&D effectiveness
A study co-authored by Professor Stylianos Kavadias and Dr Nektarios Oraiopoulos at University of Cambridge Judge Business School, is featured in the Forbes article. The study demonstrates “how pharmaceutical executives can impact the success of their research and development” programs…
Pharma shift
The pharmaceutical industry's focus on procedures and dealmaking could change significantly in this uncertain period, five Cambridge Executive MBA graduates say in a webinar for the What's Next? How to Survive and Thrive in a Post COVID-19 World series. Here's…
Biotech vs big pharma
Most approved "priority" medicines are developed by biotech rather than large pharmaceutical firms, says a two-decade study at the University of Cambridge Judge Business School. Biotech companies created 40 per cent more US Food & Drug Administration-approved "priority" drugs than…
Manhattan Project?
A "multiple-shots-on-goal" approach is needed to find coronavirus drugs, Cambridge Judge academics say in California Management Review. A many-shots-on-goal approach - not command and control - will most effectively develop vaccines and treatments for COVID-19 (coronavirus), Cambridge Judge Business School academics say in a new California Management Review article. Professor Christoph Loch While some have suggested…
